The GMRx2 trial in adults with high blood pressure (BP) demonstrated that after 12 weeks, a low-dose single-pill combination of telmisartan, amlodipine, and indapamide significantly reduced BP levels compared to several dual combinations (telmisartan with amlodipine, telmisartan with indapamide, or amlodipine with indapamide). Adverse events did not differ between the groups. This novel therapeutic option could improve high BP control.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2024.11.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Simplified Approach to Managing Newly Diagnosed Patients with Mild-to-Moderate Hypertension in Routine Clinical Practice.
Adv Ther
December 2024
Global Medical and Patient Affairs, Servier, Suresnes, France.
Introduction: The aim of the observational SIMPLE study was to assess real-life effectiveness and safety of a single-pill combination (SPC) of perindopril arginine/amlodipine in a broad range of subjects with newly diagnosed mild-to-moderate hypertension treated in Canadian general practice.
Methods: Treatment-naïve participants aged 18-65 years with mild-to-moderate hypertension, whose physicians decided to initiate the perindopril/amlodipine SPC, were recruited from Canadian clinical practice from October 2017 to February 2019. Participants were followed at 3- (M3) and 6-month (M6) visits after treatment initiation.
Leveraging Green Chromatography in Quality-by-Design-Driven Study for the Simultaneous Analysis of Essential Single-Pill Antidiabetic Drug Combinations.
J Sep Sci
December 2024
Natural and Medical Sciences Research Center, University of Nizwa, Nizwa City, Oman.
Micellar liquid chromatography (MLC) has proven beneficial efficiency and ecological impact for routine quality control activities. In the proposed study, cyrene was investigated for the first time, together with other green additives, as a novel safe organic solvent in reversed-phase MLC. Quality-by-design (QbD) approach screened their effect on the separation performance.
View Article and Find Full Text PDFEffect of three-drug single-pill antihypertensive combinations in patients with uncontrolled hypertension.
Int Urol Nephrol
December 2024
CMH Institute of Medical Sciences, CIMS, Multan, Pakistan.
Olmesartan: 360-degree Perspectives Befitting an Angiotensin Receptor Blocker.
J Assoc Physicians India
December 2024
Medical Affairs, Department of Medical Affairs, Macleods Pharmaceuticals, Mumbai, Maharashtra, India, ORCID: https://orcid.org/0009-0002-2663-4645, Corresponding Author.
India has a high burden of hypertension (HTN), which is often poorly controlled, leading to hypertension-mediated organ damage (HMOD). In the management of HTN, angiotensin receptor blockers (ARBs) assume prime importance, being first-line agents for most patient subgroups. Olmesartan is a highly efficacious ARB that demonstrates sustained blood pressure (BP) reduction over 24 hours.
View Article and Find Full Text PDFSingle-pill combination therapy is the standard of care for hypertension, but it is time for the next step: Implementation.
Med
December 2024
Masira Research Institute, Universidad de Santander (UDES), Bucaramanga, Colombia; Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador. Electronic address:
The GMRx2 trial in adults with high blood pressure (BP) demonstrated that after 12 weeks, a low-dose single-pill combination of telmisartan, amlodipine, and indapamide significantly reduced BP levels compared to several dual combinations (telmisartan with amlodipine, telmisartan with indapamide, or amlodipine with indapamide). Adverse events did not differ between the groups. This novel therapeutic option could improve high BP control.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!